This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fiegl, H. Articles by Widschwendter, M. Search for Related Content PubMed PubMed Citation Articles by Fiegl, H. Articles by Widschwendter, M.

Breast Cancer DNA Methylation Profiles in Cancer Cells and Tumor Stroma: Association with HER-2/neu Status in Primary Breast Cancer

Departments of ¹ Obstetrics and Gynecology, and ² Medical Statistics, Informatics, and Health Economics, Innsbruck Medical University, Innsbruck, Austria; Departments of ³ Biochemistry and Molecular Biology, and ⁴ Surgery, University of Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, California; and ⁵ Department of Gynaecological Oncology, Institute for Women's Health, University College London, United Kingdom

Requests for reprints: Martin Widschwendter, Department of Gynaecological Oncology, Institute for Women's Health, University College London, EGA Hospital, 2nd Floor, Huntley Street, London, WC1E 6DH, United Kingdom. Phone: 44-20-7380-6807; Fax: 44-20-7380-9748; E-mail: M.Widschwendter{at}ucl.ac.uk.

The HER-2/neu gene is amplified and overexpressed in 20% to 30% of invasive breast carcinomas and is associated with increased metastatic potential and less tamoxifen sensitivity. We generated the DNA methylation profiles of 143 human breast tumors and found significant differences in HER-2/neu expression and DNA methylation of five genes. For three of these five genes [PGR (coding for the progesterone receptor), HSD17B4 (coding for type 4 17-ß-hydroxysteroid dehydrogenase, an enzyme that mainly degrades active 17-ß-estradiol into inactive metabolites), and CDH13 (coding for H-cadherin)] a higher prevalence of DNA methylation in HER-2/neu-positive cancers was confirmed in an independent set of microdissected primary breast cancers. DNA methylation was not only present in cancer cells but also in the tumor stroma fraction. Of the isolated fractions in HER-2/neu-positive versus -negative cancers, 27.1% versus 10.5%, respectively, showed DNA methylation of the five genes (P = 0.011, Fisher's exact test). In Her-2++/+++ breast cancers, HSD17B4 mRNA expression was inversely associated with HSD17B4 methylation (P = 0.04). These data support the view that in addition to HER-2/neu-associated signaling, epigenetic changes in cancer as well as in tumor stroma cells might attribute to the specific biological features of HER-2/neu-positive cancers. (Cancer Res 2006; 66(1): 29-33)

This article has been cited by other articles:

				A. Hadnagy, R. Beaulieu, and D. Balicki Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics Mol. Cancer Ther., April 1, 2008; 7(4): 740 - 748. [Abstract] [Full Text] [PDF]

				L. W. Hebbard, M. Garlatti, L. J.T. Young, R. D. Cardiff, R. G. Oshima, and B. Ranscht T-cadherin Supports Angiogenesis and Adiponectin Association with the Vasculature in a Mouse Mammary Tumor Model Cancer Res., March 1, 2008; 68(5): 1407 - 1416. [Abstract] [Full Text] [PDF]

				A. A. Melnikov, D. M. Scholtens, E. L. Wiley, S. A. Khan, and V. V. Levenson Array-Based Multiplex Analysis of DNA Methylation in Breast Cancer Tissues J. Mol. Diagn., January 1, 2008; 10(1): 93 - 101. [Abstract] [Full Text] [PDF]